Orphan Drug Regulation: A missed opportunity for children and adolescents with cancer

Keyphrases

• Children with Cancer 100%
• Marketing Authorization 100%
• Young Cancer Patients 100%
• Orphan Regulation 100%
• Orphan Drug Designation 100%
• Malignancy 66%
• Oncology 66%
• Summary of Product Characteristics (SmPC) 66%
• Europe 33%
• Acute Myeloid Leukemia 33%
• Pediatric 33%
• Acute Lymphoblastic Leukemia 33%
• Soft Tissue Sarcoma 33%
• Graft-versus-host Disease (GvHD) 33%
• Innovative Therapies 33%
• European Medicines Agency 33%
• High-risk Neuroblastoma 33%
• Human Use 33%
• Medicinal Products 33%
• Waiver 33%
• Regulatory Environment 33%
• High-grade Glioma 33%
• Pediatric Medicine 33%
• Orphan Drugs 33%
• Medicines Regulation 33%
• Pediatric Use 33%
• Unituxin 33%
• Pediatric Investigation Plan 33%
• Product Information 33%
• Subependymal Giant Cell Astrocytoma 33%
• Orphan Drug Development 33%

Medicine and Dentistry

• Malignant Neoplasm 100%
• Orphan Drug 100%
• Pediatrics 50%
• Medicine 37%
• Cancer 25%
• Oncology 25%
• Acute Myeloid Leukemia 12%
• Ganglioneuroblastoma 12%
• Acute Lymphoblastic Leukemia 12%
• Soft Tissue Sarcoma 12%
• Graft Versus Host Reaction 12%
• Ganglioglioma 12%
• Experimental Therapy 12%
• Everolimus 12%
• Subependymal Giant Cell Astrocytoma 12%
• Dinutuximab 12%